{"id":71441,"date":"2026-05-20T11:35:00","date_gmt":"2026-05-20T11:35:00","guid":{"rendered":"https:\/\/medsbase.com\/hmg-peptide\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"hmg-peptide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/hmg-peptide\/","title":{"rendered":"HMG (Human Menopausal Gonadotropin \/ Menotropin) \u2014 Pharmaceutical Grade"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Quick Answer \u2014 What is HMG (pharmaceutical-grade)?<\/h3>\n<p style=\"margin: 0;\"><strong>HMG<\/strong> (Gonadotrophine m\u00e9nopausique humaine, \u00e9galement appel\u00e9e <strong>m\u00e9notropine<\/strong>; CAS 61489-71-2) est une pr\u00e9paration glycoprot\u00e9ique hormonale d\u00e9riv\u00e9e d'urine contenant une bioactivit\u00e9 \u00e9gale de LH et FSH (75 UI LH + 75 UI FSH par flacon, le ratio standard 1:1). Purifi\u00e9e \u00e0 partir de l'urine de femmes m\u00e9nopaus\u00e9es \u2014 dont la production hypophysaire de gonadotrophines est naturellement \u00e9lev\u00e9e par l'absence d'inhibition par r\u00e9troaction n\u00e9gative \u2014 l'HMG est l' <strong>agoniste double LHCGR + FSHR<\/strong> in endocrine pharmacology and the reference tool for protocols that need simultaneous Leydig-cell \/ theca-cell steroidogenesis (LH side) and Sertoli-cell \/ granulosa-cell action (FSH side). The supplied pharmaceutical-grade material is the urinary-extracted glycoform at \u226599% HPLC purity. <em>For clinical studies use only.<\/em> Distinct des pr\u00e9parations cliniques de m\u00e9notropine (Menopur, Menogon, Repronex).<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Classe de compos\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pr\u00e9paration de glycoprot\u00e9ine-hormone \u2014 m\u00e9lange fixe 1:1 de l'activit\u00e9 biologique de LH et FSH ; double agoniste des r\u00e9cepteurs LH\/CG (LHCGR) + r\u00e9cepteur FSH (FSHR) ; pr\u00e9paration d'hormone peptidique<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nom chimique<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Gonadotrophine M\u00e9nopausique Humaine (M\u00e9notropine ; pr\u00e9paration extraite d'urine ; synonymes : hMG, urofollitropine-avec-LH, gonadotrophine m\u00e9nopausique)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">61489-71-2 (m\u00e9notropine \/ pr\u00e9paration mixte hMG)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Composants Actifs<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>LH<\/strong> (hormone lut\u00e9inisante, h\u00e9t\u00e9rodim\u00e8re ~30 kDa ; \u03b1 92 aa + \u03b2 121 aa, glycosyl\u00e9e) \u2014 75 UI par flacon ; <strong>FSH<\/strong> (hormone folliculo-stimulante, h\u00e9t\u00e9rodim\u00e8re ~30 kDa ; \u03b1 92 aa + \u03b2 111 aa, glycosyl\u00e9e) \u2014 75 UI par flacon. La sous-unit\u00e9 \u03b1 est commune \u00e0 la LH, FSH, HCG et TSH ; les sous-unit\u00e9s \u03b2 conf\u00e8rent la sp\u00e9cificit\u00e9 du r\u00e9cepteur. Les deux gonadotrophines sont largement N- et O-glycosyl\u00e9es.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Rapport d'Activit\u00e9 Biologique<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Activit\u00e9 LH:FSH = 1:1 (le rapport standard hMG depuis la standardisation de la puissance \u00e0 la fin des ann\u00e9es 1990 ; les deux activit\u00e9s mesur\u00e9es par bioessai de l'OMS contre les standards de r\u00e9f\u00e9rence internationaux)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>HCG Co-Purification (studies-relevant)<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Une caract\u00e9ristique des pr\u00e9parations hMG d\u00e9riv\u00e9es d'urine : les analyses de composition publi\u00e9es rapportent qu'environ <strong>95% de l'activit\u00e9 biologique m\u00e9di\u00e9e par le r\u00e9cepteur LH in vivo est attribuable \u00e0 la trace de HCG co-purifi\u00e9e \u00e0 partir d'urine postm\u00e9nopausique<\/strong> (Wolfenson et\u00a0al. 2005 and others). HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h half-life vs LH&#8217;s ~20 min \u2014 so even small HCG amounts dominate the in-vivo LH-equivalent signal. Users should be aware of this when comparing hMG to pure recombinant LH (Luveris) preparations.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>M\u00e9canisme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Double agonisme des GPCR. <strong>LHCGR<\/strong> (Coupl\u00e9 \u00e0 Gs, cellules de Leydig\/th\u00e8que\/granulosa\/corps jaune) \u2192 cascade cAMP-PKA-StAR-CYP17A1 \u2192 biosynth\u00e8se des androg\u00e8nes. <strong>FSHR<\/strong> (Coupl\u00e9 \u00e0 Gs, cellules de Sertoli chez l'homme\/cellules de la granulosa chez la femme) \u2192 cascade cAMP-PKA-CYP19A1\/aromatase \u2192 soutien \u00e0 la spermatogen\u00e8se (homme) ou conversion des androg\u00e8nes en \u0153strog\u00e8nes + maturation folliculaire (femme). L'activation double est ce qui distingue l'hMG des pr\u00e9parations de LH pure (Luveris\/rLH) ou de FSH pure (Gonal-F\/Puregon\/rFSH).<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>S\u00e9quence<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pr\u00e9paration mixte \u2014 la LH et la FSH sont toutes deux des glycoprot\u00e9ines h\u00e9t\u00e9rodim\u00e9riques. Sous-unit\u00e9 \u03b1 (commune) ~92 aa, identique pour LH\/FSH\/HCG\/TSH. Sous-unit\u00e9 \u03b2 de la LH ~121 aa, sous-unit\u00e9 \u03b2 de la FSH ~111 aa. S\u00e9quences compl\u00e8tes disponibles sur UniProt : LH\u03b2 (P01229), FSH\u03b2 (P01225), GPH\u03b1 (P01215).<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formule mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pr\u00e9paration glycoprot\u00e9ique extraite d'urine \u2014 h\u00e9t\u00e9rodim\u00e8res de FSH (\u03b1 92aa + \u03b2 111aa) + LH (\u03b1 92aa + \u03b2 121aa) dans un rapport d'activit\u00e9 biologique ~1:1. Pas de formule mol\u00e9culaire unique en raison du motif de glycosylation h\u00e9t\u00e9rog\u00e8ne dans la pr\u00e9paration.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Demi-vie plasmatique<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Activit\u00e9 FSH : demi-vie terminale ~30\u201340 h (d\u00e9pendante de la sialylation, similaire aux autres hormones glycoprot\u00e9iques). Activit\u00e9 LH dans l'hMG : nominalement ~10\u201320 h (mais en pratique d\u00e9termin\u00e9e par la fraction de HCG co-purifi\u00e9e avec une demi-vie de 33\u201337 h \u2014 voir note ci-dessus sur la co-purification de HCG).<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white amorphous powder with mannitol or lactose stabilising matrix; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599 % (v\u00e9rifi\u00e9 par HPLC) ; le dosage biologique de l'OMS confirme l'activit\u00e9 LH et FSH \u00e0 75 UI chacune comme indiqu\u00e9. Certificat d'analyse disponible sur demande.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Reconstituer dans de l'eau bact\u00e9riostatique \u00e0 1,0 mL par flacon \u2192 solution m\u00e8re de travail \u00e0 75 UI LH + 75 UI FSH par mL ; autres dilutions selon protocole. Le lyophilisat se dissout rapidement par agitation douce. <strong>Ne pas agiter ; ne pas vortexer<\/strong> \u2014 un m\u00e9lange \u00e0 haute cisaillement dissocie les h\u00e9t\u00e9rodim\u00e8res \u03b1\/\u03b2 des composants LH et FSH.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C non ouvert pour le stock de travail \u00e0 court terme ; \u221220 \u00b0C pour le stockage \u00e0 long terme (stable \u226536 mois \u00e0 \u221220 \u00b0C ; \u226518 mois \u00e0 2\u20138 \u00b0C). Reconstitu\u00e9 : 2\u20138 \u00b0C, \u00e0 utiliser dans les ~30 jours. Prot\u00e9ger de la lumi\u00e8re. <strong>Ne pas congeler le mat\u00e9riel reconstitu\u00e9<\/strong> \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation dissocient les h\u00e9t\u00e9rodim\u00e8res \u03b1\/\u03b2 de LH et FSH et d\u00e9truisent la bioactivit\u00e9.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que l'HMG (M\u00e9notropine) ?<\/h2>\n<p><strong>HMG<\/strong> \u2014 La Gonadotrophine M\u00e9nopausique Humaine, \u00e9galement appel\u00e9e <strong>m\u00e9notropine<\/strong> (CAS 61489-71-2) \u2014 is a urinary-derived glycoprotein-hormone preparation containing equal amounts of LH (luteinising hormone) and FSH (follicle-stimulating hormone) bioactivity, standardised at 75 IU of each per vial. It is purified by ion-exchange and gel-filtration chromatography from the pooled urine of postmenopausal women, who have naturally elevated pituitary gonadotropin output (LH and FSH typically 50\u2013100+ mIU\/mL each) due to the loss of ovarian negative-feedback inhibition that accompanies menopause. The &#8220;menopausal&#8221; in the name refers to this source: postmenopausal urine is the most concentrated natural source of LH and FSH available for industrial-scale purification, and hMG has been produced from this source since the early 1960s (the original Cesare Serono-developed Pergonal preparation). The compositional refinement of hMG has evolved substantially over the decades \u2014 earlier preparations had highly variable LH:FSH ratios and significant protein-impurity loads; modern preparations (the basis of our pharmaceutical-grade material) are standardised at 75:75 IU bioactivity per vial with \u226599% HPLC purity. hMG is the canonical dual-gonadotropin pharmacological tool. Where HCG selectively activates the LHCGR, where pure-LH (recombinant Luveris) selectively activates the LHCGR at physiological half-life, where pure-FSH (recombinant Gonal-F \/ Puregon) selectively activates the FSHR, hMG activates both receptors simultaneously at a fixed 1:1 ratio. The two receptors are expressed on different cell populations within the gonad \u2014 LHCGR on Leydig cells \/ theca cells \/ luteinised granulosa \/ corpus luteum; FSHR on Sertoli cells \/ mural granulosa \u2014 so dual activation produces a complete physiological gonadotropin stimulus that more closely mimics endogenous mid-cycle pituitary output than either receptor activated alone. <strong>A studies-relevant nuance: HCG co-purification.<\/strong> Published compositional analyses of urinary-derived hMG preparations report that the bulk of the in-vivo LH-receptor bioactivity is actually attributable to trace HCG co-purified from postmenopausal urine \u2014 approximately 95% of LH-receptor-mediated bioactivity by some analyses (Wolfenson et\u00a0al., 2005). This is because HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h plasma half-life versus LH&#8217;s ~20 min, so even small HCG amounts dominate the cumulative in-vivo LH-equivalent signal. This is part of why hMG produces sustained Leydig-cell stimulation despite the nominal &#8220;LH activity&#8221; of LH itself being short-lived. For protocols where this distinction matters (pure-LH pharmacology vs HCG-contaminated mixed-LH signal), recombinant LH (Luveris) is the cleaner tool; for protocols where dual LHCGR + FSHR activation at physiological 1:1 ratio is the goal, hMG is the canonical reference. <\/p>\n<h2>M\u00e9canisme d'action \u2014 Activation duale des r\u00e9cepteurs LHCGR + FSHR<\/h2>\n<p>Le m\u00e9canisme d'action de l'hMG est la somme duale de ses deux activit\u00e9s composantes, toutes deux bien caract\u00e9ris\u00e9es en pharmacologie endocrinienne :<\/p>\n<ul>\n<li><strong>LH (et HCG co-purifi\u00e9) \u2192 activation du LHCGR<\/strong> \u2014 La composante LH (et la trace de HCG co-purifi\u00e9e \u00e0 partir d'urine post-m\u00e9nopausique) se lie au r\u00e9cepteur LH\/CG sur les cellules de Leydig (testicule) et les cellules th\u00e9cales \/ granulosa \/ lut\u00e9ales (ovaire). Le couplage Gs augmente l'AMPc, active la PKA, r\u00e9gule \u00e0 la hausse le transport mitochondrial du cholest\u00e9rol m\u00e9di\u00e9 par StAR, et induit les enzymes st\u00e9ro\u00efdog\u00e8nes CYP11A1 \/ CYP17A1 \/ 3\u03b2-HSD \/ 17\u03b2-HSD \u2014 conduisant \u00e0 la biosynth\u00e8se de novo de testost\u00e9rone (homme) ou d'androst\u00e8nedione (femme).<\/li>\n<li><strong>FSH \u2192 activation du FSHR<\/strong> \u2014 La composante FSH se lie au r\u00e9cepteur FSH sur les cellules de Sertoli (testicule) et les cellules granulosa murales (ovaire). Le FSHR est \u00e9galement coupl\u00e9 \u00e0 Gs, mais son programme en aval est distinct : dans les cellules de Sertoli, l'activation du FSHR stimule la prot\u00e9ine de liaison aux androg\u00e8nes (ABP), l'inhibine B, et le programme de soutien structurel qui soutient la spermatogen\u00e8se ; dans les cellules granulosa, l'activation du FSHR stimule la CYP19A1 (aromatase), convertissant les androg\u00e8nes d\u00e9riv\u00e9s des cellules th\u00e9cales en \u0153strog\u00e8nes, et favorise la maturation folliculaire jusqu'aux stades antral et pr\u00e9-ovulatoire.<\/li>\n<li><strong>Mod\u00e8le \u00e0 deux cellules et deux gonadotrophines<\/strong> \u2014 Le cadre endocrinien classique. Dans le testicule masculin, les cellules de Leydig stimul\u00e9es par la LH produisent de la testost\u00e9rone, qui diffuse dans les cellules de Sertoli adjacentes o\u00f9 la prot\u00e9ine de liaison aux androg\u00e8nes induite par la FSH et la machinerie m\u00e9tabolique des cellules de Sertoli la convertissent en un microenvironnement \u00e0 haute concentration de testost\u00e9rone intratesticulaire n\u00e9cessaire \u00e0 la spermatogen\u00e8se. Dans l'ovaire f\u00e9minin, les cellules th\u00e9cales stimul\u00e9es par la LH produisent des androg\u00e8nes, qui diffusent dans les cellules granulosa adjacentes o\u00f9 l'aromatase induite par la FSH les convertit en \u0153strog\u00e8nes. Le mod\u00e8le \u00e0 deux cellules et deux gonadotrophines est le cadre canonique, et l'hMG est l'outil pharmacologique canonique pour engager simultan\u00e9ment les deux moiti\u00e9s de ce mod\u00e8le.<\/li>\n<li><strong>D\u00e9sensibilisation des r\u00e9cepteurs et tachyphylaxie<\/strong> \u2014 Both LHCGR and FSHR undergo arrestin-mediated desensitization after sustained agonist exposure. Repeated high-dose hMG dosing can produce receptor downregulation \u2014 a well-documented phenomenon in published gonadotropin-pharmacology studies relevant to chronic-dosing protocols.<\/li>\n<li><strong>R\u00e9troaction hypothalamo-hypophysaire<\/strong> \u2014 As with HCG, hMG-driven gonadal steroid output feeds back to the hypothalamus and pituitary to suppress endogenous GnRH and LH\/FSH secretion. In the context of HPG-suppression studies (testosterone replacement, AAS exposure, pharmacological GnRH antagonism), hMG bypasses the hypothalamic-pituitary blockade by acting directly at the gonadal receptors \u2014 preserving both Leydig-cell function (LH side) and Sertoli-cell \/ spermatogenesis-support function (FSH side) simultaneously, which is what distinguishes hMG from pure-HCG protocols in this context.<\/li>\n<\/ul>\n<p>The pharmacokinetic profile of hMG broadly mirrors that of its components: FSH activity persists with 30\u201340 h terminal half-life, LH-equivalent activity is dominated by the long-half-life co-purified HCG (33\u201337 h), and the combined preparation produces sustained 24\u201372 h dual gonadotropin stimulation per dose. Typical protocol dosing is 75\u2013225 IU SC daily in rodent or human-subject studies \u2014 equivalent to 1\u20133 vials of the 75 IU strength. <\/p>\n<h2>Published Evidence<\/h2>\n<p>hMG is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Pharmacologie des gonadotrophines \u2014 la r\u00e9f\u00e9rence canonique des r\u00e9cepteurs doubles<\/strong> \u2014 most-cited dual LHCGR + FSHR agonist in published gonadotropin studies; standard reference compound for dissecting LH-only vs FSH-only vs combined gonadotropin signalling<\/li>\n<li><strong>Spermatogenesis induction studies<\/strong> \u2014 in hypogonadotropic-hypogonadism rodent models, hMG (with or without supplementary HCG) is the canonical tool for inducing spermatogenesis by restoring both Leydig-cell testosterone production and Sertoli-cell FSH support; standard protocol cycle is 75\u2013150 IU SC three times per week for 6\u201324 months in clinical-translational studies<\/li>\n<li><strong>Female ovarian-stimulation studies<\/strong> \u2014 the historical foundation tool of in-vitro fertilisation studies; hMG drives follicular development through the antral and pre-ovulatory stages in published ovulation-induction protocols, typically combined with HCG as ovulation trigger; widely used in studies on polycystic ovary syndrome (PCOS), unexplained infertility, and assisted reproductive technologies<\/li>\n<li><strong>Two-cell two-gonadotropin model studies<\/strong> \u2014 the canonical framework of gonadal steroidogenesis pharmacology; hMG is the standard tool for activating both halves of the model simultaneously; published Sertoli-Leydig co-culture and theca-granulosa co-culture uses hMG to recapitulate the physiological dual-receptor stimulus<\/li>\n<li><strong>HPG-axis suppression-recovery<\/strong> \u2014 in published studies models where endogenous LH\/FSH has been suppressed (by exogenous testosterone, AAS exposure, or GnRH antagonism), hMG preserves both Leydig-cell function and Sertoli-cell function by direct gonadal receptor activation \u2014 distinguishing it from HCG-only protocols which preserve only LH-side function and risk Sertoli-cell atrophy<\/li>\n<li><strong>Pharmacologie comparative vs LH pure \/ FSH pure \/ HCG<\/strong> \u2014 les comparaisons publi\u00e9es t\u00eate-\u00e0-t\u00eate de l'hMG vs la LH recombinante (Luveris), la FSH recombinante (Gonal-F \/ Puregon), l'HCG recombinante (Ovidrel) et diverses combinaisons sont nombreuses ; l'hMG est la r\u00e9f\u00e9rence mixte 1:1 d'origine urinaire contre laquelle toutes ces substances sont \u00e9valu\u00e9es<\/li>\n<li><strong>D\u00e9veloppement folliculaire et biologie des cellules de la granulosa<\/strong> \u2014 published ex-vivo follicular culture and primary granulosa-cell uses hMG to drive simultaneous theca-cell androgen production and granulosa-cell aromatase induction \u2014 the most physiologically relevant in-vitro stimulus available<\/li>\n<li><strong>Biologie du corps jaune<\/strong> \u2014 sustained LHCGR activation by the LH component (and co-purified HCG) maintains corpus-luteum function and progesterone production; used in studies on the luteal phase and luteo-placental transition<\/li>\n<\/ul>\n<p>For broader context on HPG-axis and reproductive-system peptides in this catalogue, see <a href=\"https:\/\/medsbase.com\/fr\/hcg-peptide\/\">HCG (Gonadotrophine Chorionique Humaine)<\/a> (agoniste pur du LHCGR \u2014 comparaison directe ; activit\u00e9 uniquement du c\u00f4t\u00e9 LH), <a href=\"https:\/\/medsbase.com\/fr\/kisspeptin-10\/\">Kisspeptine-10<\/a> (l'agoniste Kiss1R hypothalamique en amont \u2014 induit la pulsatilit\u00e9 endog\u00e8ne de la GnRH), <a href=\"https:\/\/medsbase.com\/fr\/pt-141\/\">PT-141 (Bremelanotide)<\/a> (melanocortin-receptor pharmacology \u2014 sexual-function studies), and <a href=\"https:\/\/medsbase.com\/fr\/oxytocin-acetate\/\">Ac\u00e9tate d'ocytocine<\/a> (peptide hormone posthypophysaire). Parcourez l'int\u00e9gralit\u00e9 de <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">peptides &amp; compounds catalog<\/a>. <\/p>\n<h2>Forces et concentrations disponibles<\/h2>\n<p>MedsBase stocks HMG (urinary-extracted menotropin) in a single lyophilized vial strength calibrated to the standard 1:1 LH:FSH bioactivity unit. The vial is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentration du flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>75 UI LH + 75 UI FSH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength (the international-reference unit dose) \u2014 single-dose dual-gonadotropin stimulation, spermatogenesis-induction protocols (75\u2013225 IU SC three times per week), ovarian-stimulation studies, two-cell two-gonadotropin co-culture stimulation, comparative pharmacology vs recombinant pure-LH and pure-FSH preparations<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The 75:75 IU vial is the international-reference dose unit and the format used in essentially all published gonadotropin studies and clinical practice. Multiple-vial dosing (150 IU, 225 IU per administration) is standard for higher-dose protocols. The 30-vial pack is the more economical purchase per-IU for extended-cycle or multi-cohort protocols. <\/p>\n<h2>Comparaison \u2014 HMG vs HCG<\/h2>\n<p><a href=\"https:\/\/medsbase.com\/fr\/hcg-peptide\/\">HCG<\/a> et hMG sont les deux pr\u00e9parations de gonadotrophines d'origine urinaire dans ce catalogue, et elles ciblent le syst\u00e8me des r\u00e9cepteurs aux gonadotrophines de mani\u00e8re m\u00e9canistiquement distincte. HCG est un <em>pur<\/em> agoniste des r\u00e9cepteurs LH\/CG \u2014 activation exclusive des cellules de Leydig \/ th\u00e8ques. hMG est la pr\u00e9paration <em>double<\/em> LH + FSH preparation \u2014 engages both halves of the two-cell two-gonadotropin model simultaneously. The choice between them in studies depends on whether the protocol needs LH-side activation alone or combined LH-side + FSH-side activation. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HMG (M\u00e9notrophine)<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HCG<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Composition<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">M\u00e9lange fixe 1:1 : LH 75 UI + FSH 75 UI par flacon (+ traces de HCG qui dominent le signal LH \u00e9quivalent in vivo)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">HCG pur (extrait urinaire) \u2014 glycoprot\u00e9ine unique<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>R\u00e9cepteurs activ\u00e9s<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">LHCGR <em>et<\/em> FSHR \u2014 activation double des r\u00e9cepteurs aux gonadotrophines<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">LHCGR uniquement \u2014 r\u00e9cepteur unique<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Source<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Urine post-m\u00e9nopausique<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Urine de femmes enceintes (uHCG) ou cellules CHO recombinantes (rHCG)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best applications<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Spermatogenesis induction (preserves Sertoli-cell function), ovarian follicular stimulation, two-cell two-gonadotropin model studies, dual-receptor pharmacology<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Leydig-cell-only stimulation, ovulation triggering (LH-surge mimic), Leydig-cell-specific HPG-suppression-recovery, LHCGR pharmacology<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Demi-vie plasmatique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">FSH ~30\u201340 h ; activit\u00e9 \u00e9quivalente \u00e0 la LH domin\u00e9e par la HCG co-purifi\u00e9e (33\u201337 h)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">33\u201337 h (phase terminale)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose typique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">75\u2013225 UI SC (1\u20133 flacons) par administration ; 3\u00d7\/semaine dans les protocoles chroniques<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">500\u20135,000 UI SC \/ IM (bolus unique) ; 250\u2013500 UI\/jour dans les protocoles chroniques<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Unit\u00e9 de dosage par flacon<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">75 UI de bioactivit\u00e9 (la dose unitaire de r\u00e9f\u00e9rence internationale)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">5,000 ou 10,000 UI de bioactivit\u00e9<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Statut WADA<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Interdit \u00e0 tout moment chez les athl\u00e8tes masculins (S2 \u2014 Hormones peptidiques)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Interdit \u00e0 tout moment chez les athl\u00e8tes masculins (S2 \u2014 Hormones peptidiques) ; exemption pour les athl\u00e8tes f\u00e9minines<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on dual LHCGR + FSHR activation, spermatogenesis induction, or the canonical two-cell two-gonadotropin model, hMG is the standard reference compound. For studies focused on Leydig-cell-only stimulation, ovulation triggering, or HCG-specific LHCGR pharmacology, <a href=\"https:\/\/medsbase.com\/fr\/hcg-peptide\/\">HCG<\/a> est l'outil plus cibl\u00e9. Voir \u00e9galement <a href=\"https:\/\/medsbase.com\/fr\/kisspeptin-10\/\">Kisspeptine-10<\/a> for upstream hypothalamic Kiss1R \/ GnRH-pulsatility studies. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Besoin d'eau BAC ?<\/strong> La reconstitution de tout flacon lyophilis\u00e9 n\u00e9cessite de l'eau bact\u00e9riostatique st\u00e9rile. Associez ce produit \u00e0 notre <a href=\"\/fr\/bac-water\/\"><strong>Eau BAC (Eau bact\u00e9riostatique)<\/strong><\/a> \u2014 flacon multidose de 30 mL, pr\u00e9serv\u00e9 par 0,9 % d'alcool benzylique, qualit\u00e9 USP.<\/div>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> conserver les flacons lyophilis\u00e9s au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C dans leur emballage d'origine pour le stock de travail \u00e0 court terme. Pour le stockage \u00e0 long terme, congeler les flacons non ouverts \u00e0 \u221220 \u00b0C (stable \u226536 mois \u00e0 \u221220 \u00b0C ; \u226518 mois \u00e0 2\u20138 \u00b0C). Le g\u00e2teau lyophilis\u00e9 est stabilis\u00e9 par du mannitol ou du lactose et tol\u00e8re raisonnablement une exposition br\u00e8ve \u00e0 temp\u00e9rature ambiante pendant la manipulation, mais doit \u00eatre retourn\u00e9 au r\u00e9frig\u00e9rateur rapidement. Prot\u00e9ger de la lumi\u00e8re. <strong>Proc\u00e9dure de reconstitution :<\/strong> for each 75 IU vial, inject 1.0\u00a0mL of bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake) \u2014 this yields a working stock of 75 IU LH + 75 IU FSH per mL. For protocols that need higher concentrations (multi-vial pooling for higher single-dose), reconstitute 2\u20133 vials with the same 1.0\u00a0mL diluent total to give 150\u2013225 IU\/mL. <strong>Tourbillonner doucement pour dissoudre \u2014 ne pas agiter, ne pas vortexer.<\/strong> Le m\u00e9lange \u00e0 haute cisaillement dissocie les h\u00e9t\u00e9rodim\u00e8res \u03b1\/\u03b2 des composants LH et FSH et d\u00e9truit la bioactivit\u00e9 des gonadotrophines sur leurs r\u00e9cepteurs. Le lyophilisat \u00e0 base de mannitol se dissout g\u00e9n\u00e9ralement en 30 \u00e0 60 secondes avec un l\u00e9ger tourbillonnement. <strong>R\u00e8gles de stockage critiques pour le produit reconstitu\u00e9 :<\/strong> une fois reconstitu\u00e9, conserver \u00e0 2\u20138 \u00b0C et utiliser dans les 30 jours. <strong>Ne pas congeler l'hMG reconstitu\u00e9<\/strong> \u2014 freeze-thaw cycles dissociate the LH and FSH \u03b1\/\u03b2 heterodimers (the same physical-chemistry constraint as HCG) and irreversibly destroy bioactivity. Protect from light. Discard if cloudiness, particulates, or marked colour change appears. For protocols requiring multiple aliquots, prepare aliquots at the time of reconstitution and store at 2\u20138 \u00b0C separately rather than freezing. <\/p>\n<h2>Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>Quelle est la diff\u00e9rence entre l'hMG et l'HCG ?<\/h3>\n<p><a href=\"https:\/\/medsbase.com\/fr\/hcg-peptide\/\">HCG<\/a> is a pure LH\/CG-receptor agonist \u2014 single glycoprotein hormone (CAS 9002-61-3) that binds and activates only the LHCGR on Leydig \/ theca \/ granulosa \/ luteal cells. hMG is a 1:1 mixture of LH and FSH bioactivity \u2014 distinct glycoprotein hormones (combined CAS 61489-71-2) that bind both the LHCGR (LH side) and the FSHR (FSH side). The clinical and studies consequence is that hMG produces dual-receptor stimulation that engages both halves of the two-cell two-gonadotropin model (Leydig + Sertoli in males; theca + granulosa in females), where HCG produces single-receptor stimulation of the LHCGR side only. <\/p>\n<h3>What is the HCG co-purification in hMG, and why does it matter for studies?<\/h3>\n<p>Les analyses de composition publi\u00e9es des pr\u00e9parations d'hMG d\u00e9riv\u00e9es d'urine rapportent qu'environ <strong>95 % de l'activit\u00e9 biologique m\u00e9di\u00e9e par les r\u00e9cepteurs de la LH in vivo<\/strong> is actually attributable to trace HCG co-purified from postmenopausal urine, rather than to LH itself (Wolfenson et\u00a0al., 2005). This is because HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h plasma half-life vs LH&#8217;s ~20 min \u2014 so even small amounts of co-purified HCG dominate the cumulative in-vivo LH-equivalent signal. For protocols where this distinction matters (e.g., comparing pure-LH pharmacology vs HCG-contaminated mixed-LH signal), <strong>la LH recombinante (Luveris)<\/strong> est l'outil le plus propre. Pour les protocoles n\u00e9cessitant une activation conjointe des r\u00e9cepteurs LHCGR et FSHR dans un rapport fixe de 1:1, l'hMG est la r\u00e9f\u00e9rence canonique. <\/p>\n<h3>Pourquoi l'hMG est-elle extraite des urines de femmes post-m\u00e9nopaus\u00e9es ?<\/h3>\n<p>Les femmes post-m\u00e9nopaus\u00e9es perdent l'inhibition par r\u00e9troaction n\u00e9gative ovarienne de l'axe hypothalamo-hypophysaire, ce qui augmente consid\u00e9rablement la production hypophysaire de LH et de FSH \u2014 les taux s\u00e9riques typiques de LH et de FSH post-m\u00e9nopausiques sont de 50 \u00e0 100+ mUI\/mL chacun, soit un ordre de grandeur sup\u00e9rieur aux valeurs pr\u00e9-m\u00e9nopausiques. Ces deux hormones sont ensuite \u00e9limin\u00e9es par les reins dans les urines sous forme concentr\u00e9e. Les urines post-m\u00e9nopausiques pool\u00e9es constituent donc la source naturelle la plus concentr\u00e9e de LH + FSH pour une extraction \u00e0 l'\u00e9chelle industrielle. L'industrie de l'hMG s'est construite sur cette observation au d\u00e9but des ann\u00e9es 1960 (Pergonal \u00e9tait la pr\u00e9paration originale de Serono) et se poursuit aujourd'hui, bien qu'une grande partie du march\u00e9 clinique soit pass\u00e9e aux pr\u00e9parations recombinantes de LH pure et de FSH pure. <\/p>\n<h3>What published dose ranges have been used in studies?<\/h3>\n<p>Single-dose protocol use is typically 75\u2013225 IU SC per administration (1\u20133 vials of the 75 IU strength), with 3\u00d7\/week or daily dosing in chronic protocols. Spermatogenesis-induction protocols in published hypogonadotropic-hypogonadism studies typically use 75\u2013150 IU 3\u00d7\/week for 6\u201324 months in combination with HCG (the HCG provides additional Leydig-cell stimulation). In-vitro Sertoli-cell or granulosa-cell culture protocols typically use 1\u201310 IU\/mL in growth medium. Users should consult primary literature appropriate to the species, model, and endpoint. <\/p>\n<h3>Quelle est la diff\u00e9rence entre l'hMG et la FSH recombinante pure (Gonal-F \/ Puregon) ?<\/h3>\n<p>La FSH recombinante pure (follitropine alfa \/ Gonal-F ; follitropine b\u00eata \/ Puregon ; produite dans des cellules CHO \u00e0 partir d'ADNc clon\u00e9s des sous-unit\u00e9s \u03b1 et \u03b2 de la FSH) contient <em>uniquement<\/em> FSH bioactivity \u2014 no LH, no HCG. hMG contains both LH and FSH bioactivity at 1:1 ratio (plus trace HCG). For protocols that need pure FSHR activation isolated from LHCGR signalling, recombinant FSH is the correct tool. For protocols that need combined dual-receptor activation at physiological ratio, hMG is the correct tool. Published head-to-head trials in ovarian-stimulation have compared the two with broadly equivalent follicular-development endpoints but with subtly different oestradiol-response profiles (hMG tends to produce slightly higher mid-cycle oestradiol due to the LH-side androgen substrate it provides for granulosa-cell aromatase). <\/p>\n<h3>Pourquoi l'hMG reconstitu\u00e9e ne peut-elle pas \u00eatre congel\u00e9e ?<\/h3>\n<p>La m\u00eame raison que pour l'HCG \u2014 la LH et la FSH sont toutes deux des h\u00e9t\u00e9rodim\u00e8res compos\u00e9s de deux sous-unit\u00e9s associ\u00e9es de mani\u00e8re non covalente (\u03b1 + \u03b2 chacune). L'interaction \u03b1\/\u03b2 est stable dans la poudre lyophilis\u00e9e (pas d'eau pour perturber l'interaction) et stable en solution aqueuse r\u00e9frig\u00e9r\u00e9e \u00e0 2\u20138 \u00b0C (la cin\u00e9tique de dissociation est lente \u00e0 basse temp\u00e9rature). Mais la formation de cristaux de glace lors de la cong\u00e9lation s\u00e9pare physiquement les sous-unit\u00e9s, qui ne se r\u00e9associent que de mani\u00e8re inefficace lors de la d\u00e9cong\u00e9lation. Le r\u00e9sultat est que l'hMG congel\u00e9e-d\u00e9congel\u00e9e conserve une grande fraction d'immunor\u00e9activit\u00e9 mais perd une grande fraction d'activit\u00e9 biologique. L'hMG lyophilis\u00e9e peut \u00eatre congel\u00e9e et est stable \u00e0 \u221220 \u00b0C ; l'hMG reconstitu\u00e9e ne peut pas l'\u00eatre. <\/p>\n<h3>Quel est le statut r\u00e9glementaire de l'hMG selon l'AMA ?<\/h3>\n<p>hMG \/ menotropin is on the World Anti-Doping Agency (WADA) Prohibited List under class S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). It is prohibited at all times \u2014 both in-competition and out-of-competition \u2014 for male athletes. Users conducting human-subject studies with hMG need to be aware of this regulatory status. For clinical in-vitro and rodent in-vivo studies the WADA status is informational only. <\/p>\n<h3>How does this pharmaceutical-grade hMG compare with the branded clinical preparations (Menopur, Menogon, Repronex)?<\/h3>\n<p>The branded clinical preparations are urinary-extracted menotropin (Menopur, Menogon, Repronex; the historical Pergonal preparation has been largely discontinued) packaged under various manufacturer SKUs for clinical use in assisted reproductive technologies. The pharmaceutical-grade hMG supplied here is the same urinary-extracted preparation at \u226599% HPLC purity, supplied without a clinical-use label and intended for clinical studies only. Users seeking clinical-use menotropin should obtain it through a clinical supply chain; users seeking pharmaceutical-grade material for in-vitro receptor pharmacology, rodent in-vivo work, or other clinical applications can use the material supplied here. <\/p>\n<h3>Can hMG be combined with HCG, Kisspeptin-10, or testosterone in protocols?<\/h3>\n<p>Yes \u2014 these compounds target different layers of the HPG axis and are commonly combined in published studies. The most-published combinations are hMG + HCG (the standard clinical and protocol for spermatogenesis induction in hypogonadotropic-hypogonadism models \u2014 hMG provides FSH-side support, additional HCG provides supplemental LH-side stimulation); hMG + <a href=\"https:\/\/medsbase.com\/fr\/kisspeptin-10\/\">Kisspeptine-10<\/a> (upstream + downstream dissection \u2014 kisspeptin drives endogenous GnRH while hMG provides direct gonadal stimulation); hMG + exogenous testosterone (for HPG-suppression-recovery, where the testosterone suppresses endogenous LH\/FSH and hMG bypasses the suppression by acting directly at the gonad). Reconstitute each separately and follow each compound&#8217;s specific storage rules \u2014 neither hMG nor HCG should be frozen reconstituted. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for HPG-Axis and Reproductive Studies<\/h2>\n<ul>\n<li><a href=\"\/fr\/hcg-peptide\/\"><strong>HCG (Gonadotrophine Chorionique Humaine)<\/strong><\/a> \u2014 Agoniste pur du r\u00e9cepteur LH\/CG \u2014 comparaison directe ; activit\u00e9 uniquement c\u00f4t\u00e9 LH<\/li>\n<li><a href=\"\/fr\/kisspeptin-10\/\"><strong>Kisspeptine-10<\/strong><\/a> \u2014 Agoniste hypothalamique Kiss1R \u2014 r\u00e9gulateur en amont de l'axe HPG, stimule la pulsatilit\u00e9 de la GnRH<\/li>\n<li><a href=\"\/fr\/pt-141\/\"><strong>PT-141 (Bremelanotide)<\/strong><\/a> \u2014 Melanocortin-4 receptor agonist \u2014 sexual-function studies<\/li>\n<li><a href=\"\/fr\/oxytocin-acetate\/\"><strong>Ac\u00e9tate d'ocytocine<\/strong><\/a> \u2014 Posterior pituitary nonapeptide \u2014 reproductive and social bonding<\/li>\n<li><a href=\"\/fr\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 Analogue de la GHRH \u2014 axe endocrinien diff\u00e9rent, souvent \u00e9tudi\u00e9 conjointement<\/li>\n<li><a href=\"\/fr\/bac-water\/\"><strong>Eau BAC (Eau bact\u00e9riostatique)<\/strong><\/a> \u2014 N\u00e9cessaire pour reconstituer tout flacon lyophilis\u00e9 \u2014 diluant st\u00e9rile, conserv\u00e9 avec 0,9% d'alcool benzylique<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Pr\u00e9paration glycoprot\u00e9ique double LH + FSH \u2014 ratio d'activit\u00e9 biologique 1:1 (75 UI chacune)<br \/>\n\u2705 Agoniste double canonique des r\u00e9cepteurs LHCGR + FSHR des gonadotrophines<br \/>\n\u2705 M\u00e9notrophine extraite d'urine \u00e0 partir d'urine pool\u00e9e post-m\u00e9nopausique (CAS 61489-71-2)<br \/>\n\u2705 Mod\u00e8le \u00e0 deux cellules et deux gonadotrophines \u2014 engage les cellules de Leydig+Sertoli ou th\u00e8que+granulosa<br \/>\n\u2705 Standard tool for spermatogenesis-induction &amp; ovarian-stimulation studies<\/p>\n<p><strong>HMG (Pharmaceutical Grade)<\/strong> contient de la gonadotrophine m\u00e9nopausique humaine extraite d'urine (m\u00e9notropine).<\/p>","protected":false},"featured_media":71453,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6490,6495,6492,6497,6498,6496,6493,6494],"class_list":["post-71441","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-gonadotropin","product_tag-hmg","product_tag-hpg-axis","product_tag-human-menopausal-gonadotropin","product_tag-lhcgr-fshr-agonist","product_tag-menotropin","product_tag-reproductive-research","product_tag-research-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/71441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=71441"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/71453"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=71441"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=71441"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=71441"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=71441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}